Atara Biotherapeutics
Atara Biotherapeutics
ATRA
NASDAQ
7.60
USD
-14.70%
About
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases.
Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases.
Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 54.6K |
| Three Month Average Volume | 1.7M |
| High Low | |
| Fifty-Two Week High | 49 USD |
| Fifty-Two Week Low | 4.965 USD |
| Fifty-Two Week High Date | 20 Sep 2023 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 7.6 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -20.69% |
| Thirteen Week Relative Price Change | -49.36% |
| Twenty-Six Week Relative Price Change | -64.13% |
| Fifty-Two Week Relative Price Change | -83.38% |
| Year-to-Date Relative Price Change | -49.94% |
| Price Change | |
| One Day Price Change | 7.65% |
| Thirteen Week Price Change | -45.80% |
| Twenty-Six Week Price Change | -60.56% |
| Five Day Price Change | 6.44% |
| Fifty-Two Week Price Change | -79.18% |
| Year-to-Date Price Change | -40.72% |
| Month-to-Date Price Change | -22.69% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -23.30526 USD |
| Book Value Per Share (Most Recent Quarter) | -22.60767 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -23.30526 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -22.60767 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -33.93533 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.02361 USD |
| Revenue Per Share (Trailing Twelve Months) | 13.05859 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -65.17817 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -39.90271 USD |
| Normalized (Last Fiscal Year) | -64.14559 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -65.17817 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -39.90271 USD |
| Including Extraordinary Items (Last Fiscal Year) | -65.17817 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -39.90271 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 12.14806 USD |
| Cash Per Share (Most Recent Quarter) | 7.19657 USD |
| Cash Flow Per Share (Last Fiscal Year) | -64.03831 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -36.82137 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -29.82541 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,218 |
| Cash Flow Revenue (Trailing Twelve Months) | -228 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -290.18% |
| Pretax Margin (Last Fiscal Year) | -3,220.71% |
| Pretax Margin (5 Year) | -1,559.23% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -3.65% |
| Gross Margin (Trailing Twelve Months) | 80.14% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -3,219.48% |
| Operating Margin (Trailing Twelve Months) | -287.00% |
| Operating Margin (5 Year) | -1,623.72% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3,220.88% |
| Net Profit Margin (Trailing Twelve Months) | -290.20% |
| Net Profit Margin (5 Year) | -1,559.33% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2,892.69% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 809.03% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -49.14% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 77.04% |
| EPS Change (Trailing Twelve Months) | 45.70% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 2.1M |
| Net Debt (Last Fiscal Year) | -16,158,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -194,200,000 |
| Free Cash Flow (Trailing Twelve Months) | -142,490,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -251 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -101.91% |
| Return on Assets (Trailing Twelve Months) | -99.55% |
| Return on Assets (5 Year) | -70.20% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -2,014.86% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -112.74% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -172.16% |
| Return on Investment (Trailing Twelve Months) | -256.98% |
| Return on Investment (5 Year) | -86.94% |